307 related articles for article (PubMed ID: 30742128)
1. Targeting KPNB1 overcomes TRAIL resistance by regulating DR5, Mcl-1 and FLIP in glioblastoma cells.
Zhu ZC; Liu JW; Yang C; Li MJ; Wu RJ; Xiong ZQ
Cell Death Dis; 2019 Feb; 10(2):118. PubMed ID: 30742128
[TBL] [Abstract][Full Text] [Related]
2. DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas.
Bellail AC; Tse MC; Song JH; Phuphanich S; Olson JJ; Sun SY; Hao C
J Cell Mol Med; 2010 Jun; 14(6A):1303-17. PubMed ID: 19432816
[TBL] [Abstract][Full Text] [Related]
3. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
Rosato RR; Almenara JA; Coe S; Grant S
Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
[TBL] [Abstract][Full Text] [Related]
4. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.
Gómez-Benito M; Martinez-Lorenzo MJ; Anel A; Marzo I; Naval J
Exp Cell Res; 2007 Jul; 313(11):2378-88. PubMed ID: 17462628
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of c-FLIP-short in response to TRAIL promotes survival of NSCLC cells, which could be suppressed by inhibition of Ca2+/calmodulin signaling.
Kaminskyy VO; Surova OV; Piskunova T; Zborovskaya IB; Tchevkina EM; Andera L; Zhivotovsky B
Cell Death Dis; 2013 Mar; 4(3):e522. PubMed ID: 23470529
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of euchromatin histone-lysine N-methyltransferase 2 sensitizes breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through reactive oxygen species-mediated activating transcription factor 4-C/EBP homologous protein-death receptor 5 pathway activation.
Kim SY; Hong M; Heo SH; Park S; Kwon TK; Sung YH; Oh Y; Lee S; Yi GS; Kim I
Mol Carcinog; 2018 Nov; 57(11):1492-1506. PubMed ID: 29964331
[TBL] [Abstract][Full Text] [Related]
7. High susceptibility of metastatic cells derived from human prostate and colon cancer cells to TRAIL and sensitization of TRAIL-insensitive primary cells to TRAIL by 4,5-dimethoxy-2-nitrobenzaldehyde.
Kim HB; Kim MJ; Kim DY; Lee JW; Bae JH; Kim DW; Kang CD; Kim SH
Mol Cancer; 2011 Apr; 10():46. PubMed ID: 21513580
[TBL] [Abstract][Full Text] [Related]
8. α-TEA induces apoptosis of human breast cancer cells via activation of TRAIL/DR5 death receptor pathway.
Yu W; Tiwary R; Li J; Park SK; Jia L; Xiong A; Simmons-Menchaca M; Sanders BG; Kline K
Mol Carcinog; 2010 Nov; 49(11):964-73. PubMed ID: 20886583
[TBL] [Abstract][Full Text] [Related]
9. Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism.
Ortiz-Ferrón G; Yerbes R; Eramo A; López-Pérez AI; De Maria R; López-Rivas A
Cell Res; 2008 Jun; 18(6):664-76. PubMed ID: 18458681
[TBL] [Abstract][Full Text] [Related]
10. Antimycin A sensitizes cells to TRAIL-induced apoptosis through upregulation of DR5 and downregulation of c-FLIP and Bcl-2.
Lee SJ; Kim EA; Song KS; Kim MJ; Lee DH; Kwon TK; Lee TJ
Int J Oncol; 2012 Oct; 41(4):1425-30. PubMed ID: 22842544
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL.
Hassanzadeh A; Farshdousti Hagh M; Alivand MR; Akbari AAM; Shams Asenjan K; Saraei R; Solali S
J Cell Physiol; 2018 Oct; 233(10):6470-6485. PubMed ID: 29741767
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of active caspase 8 as a mechanism of acquired TRAIL resistance in mismatch repair-proficient colon carcinoma cell lines.
Van Geelen CM; Pennarun B; Ek WB; Le PT; Spierings DC; De Vries EG; De Jong S
Int J Oncol; 2010 Oct; 37(4):1031-41. PubMed ID: 20811726
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level.
Morizot A; Mérino D; Lalaoui N; Jacquemin G; Granci V; Iessi E; Lanneau D; Bouyer F; Solary E; Chauffert B; Saas P; Garrido C; Micheau O
Cell Death Differ; 2011 Apr; 18(4):700-11. PubMed ID: 21072058
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP.
Kim YH; Jung EM; Lee TJ; Kim SH; Choi YH; Park JW; Park JW; Choi KS; Kwon TK
Free Radic Biol Med; 2008 Mar; 44(6):1055-68. PubMed ID: 18164688
[TBL] [Abstract][Full Text] [Related]
15. The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation.
Fan S; Li Y; Yue P; Khuri FR; Sun SY
Neoplasia; 2010 Apr; 12(4):346-56. PubMed ID: 20360945
[TBL] [Abstract][Full Text] [Related]
16. Vernodalol enhances TRAIL-induced apoptosis in diffuse large B-cell lymphoma cells.
Wu W; Yang Y; Deng G; Ma L; Wei G; Zheng G; Han X; He D; Zhao Y; He J; Cai Z; Yu R
Mol Carcinog; 2017 Oct; 56(10):2190-2199. PubMed ID: 28467689
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of RIP and c-FLIP in preventing liver cancer cell apoptosis induced by TRAIL.
Sun J; Luo H; Nie W; Xu X; Miao X; Huang F; Wu H; Jin X
Int J Clin Exp Pathol; 2015; 8(6):6519-25. PubMed ID: 26261530
[TBL] [Abstract][Full Text] [Related]
18. Importin β1 protein-mediated nuclear localization of death receptor 5 (DR5) limits DR5/tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced cell death of human tumor cells.
Kojima Y; Nakayama M; Nishina T; Nakano H; Koyanagi M; Takeda K; Okumura K; Yagita H
J Biol Chem; 2011 Dec; 286(50):43383-93. PubMed ID: 22020938
[TBL] [Abstract][Full Text] [Related]
19. Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression.
Syed V; Mukherjee K; Godoy-Tundidor S; Ho SM
J Cell Biochem; 2007 Oct; 102(2):442-52. PubMed ID: 17393432
[TBL] [Abstract][Full Text] [Related]
20. Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells.
Wang X; Chen W; Zeng W; Bai L; Tesfaigzi Y; Belinsky SA; Lin Y
Mol Cancer Ther; 2008 May; 7(5):1156-63. PubMed ID: 18483303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
